​

Protagonist Therapeutics Ownership | Who Owns Protagonist Therapeutics?

OverviewForecastRevenueFinancialsChart

Protagonist Therapeutics Ownership Summary

Protagonist Therapeutics is owned by 99.41% institutional investors, 1.18% insiders. Farallon capital management is the largest institutional shareholder, holding 9.53% of PTGX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 6.30% of its assets in Protagonist Therapeutics shares.

PTGX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockProtagonist Therapeutics99.41%1.18%-0.59%
SectorHealthcare Stocks 49.83%8.81%41.35%
IndustryBiotech Stocks 47.19%8.79%44.01%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Farallon capital management5.84M9.53%$202.38M
Blackrock5.76M9.39%$199.52M
Rtw investments, lp5.29M8.62%$183.17M
Bvf inc/il3.32M5.41%$115.01M
Vanguard group3.24M5.29%$112.39M
Johnson & johnson2.45M4.00%$84.86M
State street2.08M3.40%$72.15M
Jefferies financial group2.04M3.33%$70.71M
Adage capital partners gp2.00M3.26%$69.35M
Adar1 capital management1.60M2.62%$55.58M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Johnson & johnson2.45M21.18%$84.86M
Adar1 capital management1.60M10.49%$55.58M
Checkpoint capital355.00K7.42%$12.30M
Bvf inc/il3.32M3.22%$115.01M
Rtw investments, lp5.29M2.84%$183.17M
Kynam capital management, lp800.00K2.14%$27.72M
683 capital management604.45K1.58%$20.94M
Birchview capital, lp48.00K1.54%$1.66M
Eversept partners, lp505.84K1.20%$17.53M
Mangrove partners439.31K1.17%$15.22M

Top Buyers

HolderShares% AssetsChange
Millennium management958.28K0.02%915.42K
Jefferies financial group2.04M0.75%860.00K
Adar1 capital management1.60M10.49%818.28K
Qube research453.15K0.02%391.00K
Price t rowe associates inc /md/1.21M0.01%390.25K

Top Sellers

HolderShares% AssetsChange
Morgan stanley345.29K0.00%-1.53M
State street2.08M0.00%-1.19M
Fairmount funds management---931.89K
Bvf inc/il3.32M3.22%-436.70K
Marshall wace, llp572.18K0.03%-404.72K

New Positions

HolderShares% AssetsChangeValue
Eagle asset management357.63K0.07%357.63K$12.59M
Segall bryant & hamill118.56K0.07%118.56K$4.11M
Balyasny asset management57.50K0.00%57.50K$1.99M
Mirae asset global etfs32.12K0.00%32.12K$1.11M
Corebridge financial31.44K0.01%31.44K$1.09M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-11.00
Financial gravity asset management-18.00
Innealta capital-42.00
Truvestments capital-131.00
Hillsdale investment management-170.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202424627.46%61,406,0774.02%991.07%15469.23%65-7.14%
Jun 30, 20241932.66%59,030,802-1.50%960.99%91-17.27%7027.27%
Mar 31, 202418818.24%59,929,9384.29%981.09%11054.93%55-9.84%
Dec 31, 20231598.90%57,464,8621.33%951.04%71-12.35%6152.50%
Sep 30, 2023146-19.78%56,712,373-0.03%950.96%81-22.12%40-16.67%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF3.76M6.30%3.48K
Vanguard Total Stock Mkt Idx Inv1.86M3.13%-10.33K
Pacer US Small Cap Cash Cows 100 ETF1.71M2.90%-439.00
iShares Russell 2000 ETF1.50M2.52%-3.37K
SPDR® S&P Biotech ETF991.20K1.68%10.96K
T. Rowe Price Health Sciences990.99K1.68%24.27K
Vanguard Institutional Extnd Mkt Idx Tr872.32K1.46%-3.26K
UBS: US Equity Small Cap Growth744.87K1.26%-
Fidelity Small Cap Index598.86K1.02%-16.25K
SPDR® Portfolio S&P 600™ Sm Cap ETF519.65K0.88%3.92K

Recent Insider Transactions

DateNameRoleActivityValue
Nov 26, 2024MOLINA ARTURO MD Chief Medical OfficerSell$252.12K
Nov 27, 2024MOLINA ARTURO MD Chief Medical OfficerSell$717.28K
Nov 27, 2024MOLINA ARTURO MD Chief Medical OfficerSell$445.00K
Nov 26, 2024Gupta Suneel Chief Development OfficerSell$873.19K
Nov 25, 2024Gupta Suneel Chief Development OfficerSell$4.76M

Insider Transactions Trends

DateBuySell
2024 Q4-8
2024 Q3-4
2024 Q2-4
2024 Q1-7
2023 Q4-2

PTGX Ownership FAQ

Who Owns Protagonist Therapeutics?

Protagonist Therapeutics shareholders are primarily institutional investors at 99.41%, followed by 1.18% insiders and -0.59% retail investors. The average institutional ownership in Protagonist Therapeutics's industry, Biotech Stocks , is 47.19%, which Protagonist Therapeutics exceeds.

Who owns the most shares of Protagonist Therapeutics?

Protagonist Therapeutics’s largest shareholders are Farallon capital management (5.84M shares, 9.53%), Blackrock (5.76M shares, 9.39%), and Rtw investments, lp (5.29M shares, 8.62%). Together, they hold 27.54% of Protagonist Therapeutics’s total shares outstanding.

Does Blackrock own Protagonist Therapeutics?

Yes, BlackRock owns 9.39% of Protagonist Therapeutics, totaling 5.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 199.52M$. In the last quarter, BlackRock increased its holdings by 188.63K shares, a 3.39% change.

Who is Protagonist Therapeutics’s biggest shareholder by percentage of total assets invested?

Johnson & johnson is Protagonist Therapeutics’s biggest shareholder by percentage of total assets invested, with 21.18% of its assets in 2.45M Protagonist Therapeutics shares, valued at 84.86M$.

Who is the top mutual fund holder of Protagonist Therapeutics shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Protagonist Therapeutics shares, with 6.30% of its total shares outstanding invested in 3.76M Protagonist Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools